ArticleEuropean heart journal. Case reports2026
Case reports of a double threat: when cancer and hidden congenital heart defects collide: malignant tamponade unveils a hidden pulmonary venous anomaly.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant pericardial effusion is a life-threatening manifestation of advanced non-small-cell lung cancer (NSCLC). Cardiac tamponade as an initial presentation is uncommon, and coexistent pathologies can complicate diagnosis and management. Case summary: A 72-year-old man with mild chronic obstructive pulmonary disease (COPD) and a remote 2-pack-year smoking history was admitted with COVID-19 infection and possible superimposed pneumonia. Initial imaging revealed pericardial inflammation and a small effusion, raising concern for pericarditis. Subsequent echocardiography demonstrated a large pericardial effusion with tamponade physiology requiring pericardiocentesis, while cardiac magnetic resonance and computed tomography suggested possible malignancy. Cytology from pericardial and pleural fluid confirmed adenocarcinoma and bronchoscopy established stage IV epidermal growth factor-mutant NSCLC with cerebellar metastases. The patient experienced recurrent malignant effusions, managed successfully with balloon pericardiotomy and was treated with Osimertinib, resulting in sustained remission of effusions and clinical recovery. Careful review of multimodality imaging also revealed partial anomalous pulmonary venous return with significant left-to-right shunting, which may have exerted a protective hemodynamic effect on tamponade physiology. This may suggest a potential, though speculative, contribution of the anomalous pulmonary venous return to the observed tamponade physiology. At 2-year follow-up, the patient remains clinically and hemodynamically stable. Discussion: This case illustrates the interesting duality of how multiple concurrent pathologies-including COVID-19 pneumonia, pericarditis, malignant pleuro-pericardial effusions, metastatic lung adenocarcinoma, and PAPVR-can coexist and probably shape the clinical course. The case underscores the indispensable role of multimodality imaging, molecular profiling, and minimally invasive pericardial interventions in guiding diagnosis, therapy, and prognosis in complex cardio-oncology presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.